YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Clinuvel Pharmaceuticals Limited press release [https://seekingalpha.com/pr/20631591-a-decade-of-profitability-provides-foundation-for-clinuvel-s-u-s-expansion] (CLVLF [https://seekingalpha.com/symbol/CLVLF]): FY GAAP EPS of A$0.67. * Re…
CLINUVEL PHARMACEUTICALS (CLVLY [https://seekingalpha.com/symbol/CLVLY]) (CLVLF [https://seekingalpha.com/symbol/CLVLF]) announced that its American Depositary Shares (ADS) are expected to commence [https://seekingalpha.com/pr/20587437-cli…
As Australian shares continue their upward momentum, marking a third consecutive advance in Week 7, investors are keenly focused on February's earnings season, which is poised to influence market dynamics significantly. In this environment…
As Australian shares continue their upward trajectory, buoyed by a rally in the S&P 500 and anticipation surrounding upcoming inflation data, investors are closely watching how these factors might influence future Reserve Bank of Australia…
As the Australian market navigates a period of mixed sentiment, with the S&P/ASX 200 (XJO) rebounding to 8,600 points despite inflation climbing to 3.8%, investors are closely watching sectors like IT which recently lagged behind materials…
The Australian market has been navigating a period of uncertainty, with key indices fluctuating due to geopolitical events and rising inflation, while sectors like materials have shown resilience amidst these challenges. In this environmen…
As the Australian market remains relatively stable with the ASX ending slightly in the red midweek, investors are keeping a keen eye on sectors showing resilience and potential for growth, particularly within the tech space. In this enviro…
The Australian stock market has recently experienced a notable upswing, with the ASX gaining 1.3% amid strong performances in sectors like Materials and Healthcare, driven by global economic factors such as uncertainty around a potential U…
The Australian market has seen mixed performances recently, with the ASX200 retreating and IT sectors showing resilience amid broader economic uncertainties, including potential US interest rate cuts and fluctuating commodity prices. In th…
HONOLULU - Orthogonal Thinker, Inc. announced Tuesday it plans to acquire and fully consolidate Ei.Ventures, Inc., its majority-owned subsidiary, in a transaction expected to complete by the end of Q1 2026. The consolidation represents a s…
Key Insights Clinuvel Pharmaceuticals' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 39% of the business is held by the top 25 shareholders Recent purchases by…
Clinuvel Pharmaceuticals (ASX:CUV) has had a rough three months with its share price down 16%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes,…
As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term Clinuvel Pharmaceuticals…
Key Insights The projected fair value for Clinuvel Pharmaceuticals is AU$18.90 based on 2 Stage Free Cash Flow to Equity With AU$17.27 share price, Clinuvel Pharmaceuticals appears to be trading close to its estimated fair value Analyst pr…
It is hard to get excited after looking at Clinuvel Pharmaceuticals' (ASX:CUV) recent performance, when its stock has declined 20% over the past three months. However, a closer look at its sound financials might cause you to think again. G…
Key Insights Clinuvel Pharmaceuticals' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 25 shareholders own 45% of the company 13% of Clinuvel Pharmace…
While Clinuvel Pharmaceuticals Limited (ASX:CUV) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 12% in the last quarter. But that doesn't change the fact that th…
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investments often have little probability of ever…
Clinuvel Pharmaceuticals Limited CLINUVEL's CYACÊLLE CLINUVEL today launched CYACÊLLE, a next generation of polychromatic solar care. CYACÊLLE is designed to protect skin from a wide spectrum of damaging solar radiation under extreme condi…
The latest analyst coverage could presage a bad day for Clinuvel Pharmaceuticals Limited (ASX:CUV), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Both reve…
Clinuvel Pharmaceuticals (ASX:CUV) First Half 2023 Results Key Financial Results Revenue: AU$30.7m (up 25% from 1H 2022). Net income: AU$11.4m (up 94% from 1H 2022). Profit margin: 37% (up from 24% in 1H 2022). The increase in margin was d…
Clinuvel Pharmaceuticals Limited CLINUVEL Financial Performance CLINUVEL Group financial performance for the half year ended 30 December, since first commercial sales. MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summa…
Clinuvel Pharmaceuticals Limited Study in healthy volunteers shows single dose of afamelanotide reduces erythema caused by ultraviolet radiation MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical…
In this article we are going to estimate the intrinsic value of Clinuvel Pharmaceuticals Limited (ASX:CUV) by projecting its future cash flows and then discounting them to today's value. One way to achieve this is by employing the Discount…
Clinuvel Pharmaceuticals Limited Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic…
Most readers would already know that Clinuvel Pharmaceuticals' (ASX:CUV) stock increased by 4.1% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance.…
If you want to know who really controls Clinuvel Pharmaceuticals Limited (ASX:CUV), then you'll have to look at the makeup of its share registry. We can see that individual investors own the lion's share in the company with 54% ownership.…
The underwhelming share price performance of Clinuvel Pharmaceuticals Limited (ASX:CUV) in the past three years would have disappointed many shareholders. What is concerning is that despite positive EPS growth, the share price has not trac…
It's been a soft week for Clinuvel Pharmaceuticals Limited (ASX:CUV) shares, which are down 14%. But that scarcely detracts from the really solid long term returns generated by the company over five years. We think most investors would be…
Does the August share price for Clinuvel Pharmaceuticals Limited (ASX:CUV) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to today's value.…
The big shareholder groups in Clinuvel Pharmaceuticals Limited (ASX:CUV) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Warren Bu…
Clinuvel Pharmaceuticals Limited Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide Vitiligo repigmentation in CLINUVEL's CUV102 study Initial clinical studies of afamelanotide showed…
Clinuvel Pharmaceuticals Limited World-first stroke study CUV801 evaluating afamelanotide Figure 1 - CUV801 MRI-FLAIR results Individual patient data of brain scans (MRI-FLAIR) showing a reduction of the affected area in five of the six pa…
Clinuvel Pharmaceuticals Limited LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on the disproportion…
Clinuvel Pharmaceuticals Limited (ASX:CUV) shareholders might understandably be very concerned that the share price has dropped 35% in the last quarter. But that doesn't change the fact that the returns over the last five years have been v…
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Clinuvel Pharmaceuticals Limited (ASX:CUV) as an investment opportunity by estimating the company's future cash flows and discounting them to…